Skip to main content

Atara Biotherapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 7, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 7, 2025

ATRA$8.10-1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page)

SIGNA TURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Thousand Oaks, State of California, on the 7 th day of March, 2025.

Atara Biotherapeutics, Inc.
By:/s/ AnhCo Thieu Nguyen
AnhCo Thieu Nguyen
President and Chief Executive Officer

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints AnhCo Thieu Nguyen and Eric Hyllengren, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ AnhCo Thieu Nguyen
AnhCo Thieu NguyenPresident, Chief Executive Officer and Director (Principal Executive Officer)March 7, 2025
/s/ Eric Hyllengren
Eric HyllengrenChief Financial Officer and Chief Operating Officer (Duly Authorized Officer and Principal Financial and Accounting Officer)March 7, 2025
/s/ Pascal Touchon
Pascal Touchon, D.V.M.Director, ChairMarch 7, 2025
/s/ Carol G. Gallagher
Carol G. Gallagher, Pharm. D.Lead DirectorMarch 7, 2025
/s/ Matthew K. Fust
Matthew K. FustDirectorMarch 7, 2025
/s/ William K. Heiden
William K. HeidenDirectorMarch 7, 2025
/s/ Ameet Mallik
Ameet MallikDirectorMarch 7, 2025
/s/ Maria Grazia Roncarolo
Maria Grazia Roncarolo, M.D.DirectorMarch 7, 2025
/s/ Gregory Ciogoli
Gregory CiongoliDirectorMarch 7, 2025
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.